Integration of hypoxic HIF-α signaling in blood cancers

doi:10.1038/onc.2017.119

Review

. 2017 Sep 21;36(38):5331-5340.

doi: 10.1038/onc.2017.119. Epub 2017 May 22.

Integration of hypoxic HIF-α signaling in blood cancers

L Schito¹, S Rey¹, M Konopleva^{2

3}

Affiliations

¹ Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
² Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
³ Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

PMID: 28534514
DOI: 10.1038/onc.2017.119

Review

Integration of hypoxic HIF-α signaling in blood cancers

L Schito et al. Oncogene. 2017.

. 2017 Sep 21;36(38):5331-5340.

doi: 10.1038/onc.2017.119. Epub 2017 May 22.

Authors

L Schito¹, S Rey¹, M Konopleva^{2

3}

Affiliations

¹ Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
² Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
³ Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

PMID: 28534514
DOI: 10.1038/onc.2017.119

Abstract

Hypoxia (low O₂) is a fundamental microenvironmental determinant of bone marrow (BM) pathophysiology. Recent data from molecular and clinical studies indicate that hematopoiesis and leukemogenesis are dependent upon hypoxia-inducible factors (HIFs), a family of essential transcriptional activators mediating the metazoan hypoxic response. In blood cancers, the synergism between HIF overexpression and stabilization within the hypoxic BM microenvironment promotes disease progression, therapy resistance and relapse. In this review, we will summarize current advances in the understanding of HIF signaling in blood cancers and its translational implications for hypoxic-targeted therapy.

PubMed Disclaimer

Cited by

Hypoxic stress and hypoxia-inducible factors in leukemias.
Magliulo D, Bernardi R. Magliulo D, et al. Front Oncol. 2022 Aug 18;12:973978. doi: 10.3389/fonc.2022.973978. eCollection 2022. Front Oncol. 2022. PMID: 36059690 Free PMC article. Review.
Biological Aspects of mTOR in Leukemia.
Mirabilii S, Ricciardi MR, Piedimonte M, Gianfelici V, Bianchi MP, Tafuri A. Mirabilii S, et al. Int J Mol Sci. 2018 Aug 14;19(8):2396. doi: 10.3390/ijms19082396. Int J Mol Sci. 2018. PMID: 30110936 Free PMC article. Review.
HIF1/2-exerted control over glycolytic gene expression is not functionally relevant for glycolysis in human leukemic stem/progenitor cells.
Wierenga ATJ, Cunningham A, Erdem A, Lopera NV, Brouwers-Vos AZ, Pruis M, Mulder AB, Günther UL, Martens JHA, Vellenga E, Schuringa JJ. Wierenga ATJ, et al. Cancer Metab. 2019 Dec 27;7:11. doi: 10.1186/s40170-019-0206-y. eCollection 2019. Cancer Metab. 2019. PMID: 31890203 Free PMC article.
The arginase inhibitor Nω-hydroxy-nor-arginine (nor-NOHA) induces apoptosis in leukemic cells specifically under hypoxic conditions but CRISPR/Cas9 excludes arginase 2 (ARG2) as the functional target.
Ng KP, Manjeri A, Lee LM, Chan ZE, Tan CY, Tan QD, Majeed A, Lee KL, Chuah C, Suda T, Ong ST. Ng KP, et al. PLoS One. 2018 Oct 11;13(10):e0205254. doi: 10.1371/journal.pone.0205254. eCollection 2018. PLoS One. 2018. PMID: 30307989 Free PMC article.
Merger of dynamic two-photon and phosphorescence lifetime microscopy reveals dependence of lymphocyte motility on oxygen in solid and hematological tumors.
Rytelewski M, Haryutyunan K, Nwajei F, Shanmugasundaram M, Wspanialy P, Zal MA, Chen CH, El Khatib M, Plunkett S, Vinogradov SA, Konopleva M, Zal T. Rytelewski M, et al. J Immunother Cancer. 2019 Mar 18;7(1):78. doi: 10.1186/s40425-019-0543-y. J Immunother Cancer. 2019. PMID: 30885258 Free PMC article.

See all "Cited by" articles

References

1. Cancer Cell. 2006 Nov;10(5):375-88 - PubMed
1. Biophys J. 2001 Aug;81(2):675-84 - PubMed
1. Leukemia. 2002 Feb;16(2):186-95 - PubMed
1. Blood. 2001 Apr 15;97(8):2293-9 - PubMed
1. Proc Natl Acad Sci U S A. 1996 Nov 12;93(23):12969-73 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations

[1] Cancer Cell. 2006 Nov;10(5):375-88 - PubMed

[2] Cancer Cell. 2006 Nov;10(5):375-88 - PubMed

[3] Biophys J. 2001 Aug;81(2):675-84 - PubMed

[4] Biophys J. 2001 Aug;81(2):675-84 - PubMed

[5] Leukemia. 2002 Feb;16(2):186-95 - PubMed

[6] Leukemia. 2002 Feb;16(2):186-95 - PubMed

[7] Blood. 2001 Apr 15;97(8):2293-9 - PubMed

[8] Blood. 2001 Apr 15;97(8):2293-9 - PubMed

[9] Proc Natl Acad Sci U S A. 1996 Nov 12;93(23):12969-73 - PubMed

[10] Proc Natl Acad Sci U S A. 1996 Nov 12;93(23):12969-73 - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Integration of hypoxic HIF-α signaling in blood cancers

Affiliations

Integration of hypoxic HIF-α signaling in blood cancers

Authors

Affiliations

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources